CSIMarket


Igm Biosciences Inc   (IGMS)
Other Ticker:  
 


 

Igm Biosciences Inc

IGMS's Financial Statements and Analysis



Igm Biosciences Inc narrowed third quarter of 2023 net loss per share of $-1.04 compare to net loss per share of $-1.32 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.43 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -1.04 $  1 Mill
$+0.28     $+1M    



Igm Biosciences Inc 's Revenue rose by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $1 million and advanced by sequentially.


Igm Biosciences Inc is Expected to report next financial results on March 29, 2024.

More on IGMS's Income Statement



Igm Biosciences Inc 's in thethird quarter of 2023 recorded net loss of $-61.989 million, an increase from net loss of $-58.037 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-64.423 million realized in previous quarter.

More on IGMS's Growth

Igm Biosciences Inc Inventories
IGMS's Cash flow In the third quarter of 2023 company's net cash flow was $24 million, capital expenditures fell by -2.71113.72%, to $-3 millions compare to same quarter a year ago

More on IGMS's Cash flow Statement


Igm Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Igm Biosciences Inc payed $ -3.06 cash per share, on a free-cash flow basis .

Book value fell by -25.66 % sequentially to $4.26 per share, -30.91% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.26 per share from $ 5.73.

Company issued 14.46 million shares or 32.04 % in Sep 30 2023.


More on IGMS's Dividends

 Market Capitalization (Millions) 634
 Shares Outstanding (Millions) 60
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -238
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) -14
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 170




Igm Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Igm Biosciences Inc had negative $ -3.06 cash flow per share, on a free-cash flow basis .

Book value fell by -25.66 % sequentially to $4.26 per share, -30.91% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.26 per share from $ 5.73.

Company issued 14.46 million shares or 32.04 % in Sep 30 2023.


More on IGMS's Balance Sheets

 Market Capitalization (Millions) 634
 Shares Outstanding (Millions) 60
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -238
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) -14
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 170
   


  News about Igm Biosciences Inc Earnings

Igm Biosciences Inc Announces Impressive Revenue of $0.509 Million in Latest Fiscal Period

...

Igm Biosciences Inc Reports Increased Expenditure amid Rising Stock Values for Q2 2023



Igm Biosciences Inc, a company operating in the Major Pharmaceutical Preparations sector, has recently announced its financial results for the second quarter of 2023. The results indicate a significant operating loss of $-68.208 million, which is higher than the previous year's second quarter operating loss of $-59.224 million. With these figures in mind, it becomes essential to analyze the potential impact of these financial developments on the company's future prospects.
The Current Situation:
Examining the recent financial performance reveals that Igm Biosciences Inc has recorded a solid gain of 6.04% in stock value over the past five days. Over the preceding 30 days, the stock price inc...

Igm Biosciences Inc Generates $0.522 Million in Revenue for Q1 2023, Indicates Ongoing Potential for Growth

Investing in the stock market can be a risky venture, and one...


Date modified: 2023-11-14T22:12:05+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com